An observational study in COVID-19, sponsored by University Hospital Southampton NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by University Hospital Southampton NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.
Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 152nd largest by planned enrollment of the 167 observational ones that give a count, is one of 12 that started in 2023, is one of 167 observational ones, reaches primary completion later than 4 of the 31 other live ones, and was the 325th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–50 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in United Kingdom, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
Euresist Network GEIE · Sites in United Kingdom, Germany, Italy and 3 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
340 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 52 · Phase 3 66 · Phase 4 5
First in 2013; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 247 across the 172 interventional studies, 296 across the 167 observational. Of the 245 that completed or were terminated, 75 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 340 have an industry lead sponsor. The 10 most frequent:
University Hospital Southampton NHS Foundation Trust is the lead sponsor of 150 studies on the registry; 35 are open to participants now.
University Hospital Southampton NHS Foundation Trust has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
| NCT04863573Queen's University, BelfastCOVID-19 Antibody Responses In Cystic Fibrosis | 2027-08 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 340 studies in COVID-19 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People who are older, those who had underlying other health conditions and people living in poorer communities are at increased risk of complications and worse outcome from COVID-19. They are more likely to be admitted to hospital with this virus. In the UK in 2020, over 130,000 people were admitted to hospital with COVID-19. Whilst admission rates fell since then, there is a need to understand better the potential impact of the many symptoms resulting from a COVID-19 infection on patients and the health services. To achieve this, the respiratory team in the University Hospital set up a COVID-19 follow-up clinic for patients who had COVID-19 infection. In this clinic, for a period of 12 weeks patients have chest X-rays, blood tests and virtual medical consultations. The clinic has been running for three years.
This study will be conducted study to understand the expectations, preferences and experiences of patients who have been receiving care in the clinic. On one hand, patients who have received care in the clinic during the last yearwill be interviewed. On the other hand, patients who have been newly referred to the clinic will be interviewed before they start it and also after 12 weeks about how their expectations have been met. Patients will be identified by their clinical team and after consenting to take part in the study, they will be interviewed by qualitative researchers who will also analyse the interview data using scientific methods. The results of this study will help understanding whether changes are to be made to this clinic and also inform future similar services should they be needed.
The long-term consequences of COVID-19 remain unclear. People who are older, have medical comorbidities and those who live in areas of increased socio-economic deprivation are at increased risk of poor outcome and complications from COVID-19 (1).
In 2020, over 130,000 people have been admitted to hospital with COVID-19 in the UK (2). Whilst admission rates fell, the potential impact of 'post-COVID' syndromes on patients and the health services need longer-term further investigation.
The British Thoracic Society (BTS) COVID-19 Guidance advises follow-up of patients who had COVID-19, depending on whether the patient required intensive/higher care versus ward/community care.1. For mild/moderate disease, BTS recommends virtual follow-up with a chest X-ray (1). A wide range of symptoms and reduced HRQoL has been detected in these patients reinforcing the importance of a implementing a holistic approach advocated by the BTS and other guidelines (2).
The COVID follow-up service was set up in 2020 in the Southampton General Hospital to provide longer-term care to patients with COVID-19 chest symptoms. The changing nature of the pandemic and an extension of the cohort from patients discharged after hospital stay for COVID-19 infection to previously not hospitalised patients referred by GPs call for an evaluation of the COVID follow-up clinic to explore patient experiences, expectations, and preferences with this service.
The research population of interest for this study is patients followed up in the UHS COVID follow-up clinic following diagnosed COVID-19 infection. This will include all patients deemed appropriate by their clinical team to receive this clinical service
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One-to-one semi-structured interviews will be conducted with patients who have received care in the UHS COVID follow-up clinics in no more than 12 months prior to study enrolment. Interviews will be conducted at one time point
Other: Qualitative Interview
One-to-one semi-structured interviews will be conducted with patients with confirmed prior COVID-19 infection who are scheduled to receive care in the UHS COVID follow-up clinics. Interviews will be conducted before attending the first clinic appointment (baseline) and after discharge from the clinic (at 12 weeks).
Other: Qualitative Interview
Qualitative, semi-structured interview
Qualitative Interview
Experiences, preferences and expectations of patients receiving care in the UHS COVID-19 follow-up clinic
Time frame: 12 months
Plan to share: No — Throughout the study, the researchers will be working with the Public and Patient Involvement group to develop a dissemination strategy of the results to the study participants and other stakeholders and/or the public as appropriate.
Started Aug 2023 (actual). Primary completion is estimated for Oct 2023, 2 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 2 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Southampton NHS Foundation Trust →